Eisai looks to cost competitiveness and Asia as it refocuses post-Aricept business
This article was originally published in Scrip
With US revenues from its former mainstay product a shadow of what they were at this time last year, Eisai chose to focus on its affordable medicines initiatives, geographical business shift and innovative skills at an annual corporate briefing in Tokyo.
You may also be interested in...
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.